Get the Stockscreener App
20.97
1.46%
-0.31
After Hours:
20.66
-0.31
-1.48%
Uniqure Nv stock is traded at $20.97, with a volume of 3.32M.
It is down -1.46% in the last 24 hours and down -53.33% over the past month.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
See More
Previous Close:
$21.28
Open:
$21
24h Volume:
3.32M
Relative Volume:
1.39
Market Cap:
$1.45B
Revenue:
$18.09M
Net Income/Loss:
$-208.87M
P/E Ratio:
-5.9701
EPS:
-3.5125
Net Cash Flow:
$-178.15M
1W Performance:
-9.38%
1M Performance:
-53.33%
6M Performance:
+22.70%
1Y Performance:
-64.43%
1-Day Range:
$20.33
$21.75
1-Week Range:
$20.33
$23.00
52-Week Range:
$8.73
$71.50
Uniqure Nv Stock (QURE) Company Profile
Name
Uniqure Nv
Sector
Industry
Phone
1-339-970-7000
Address
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure Nv
|
20.97 | 1.45B | 18.09M | -208.87M | -178.15M | -3.5125 |
VRTX
Vertex Pharmaceuticals Inc
|
498.50 | 126.35B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
226.30 | 90.35B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
778.36 | 80.14B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
818.30 | 51.46B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
193.52 | 41.48B | 742.00K | -1.37B | -1.07B | -7.0731 |
Uniqure Nv Stock (QURE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-05-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Sep-02-26 | Resumed | William Blair | Outperform |
| Jul-30-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-18-26 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-17-26 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-11-26 | Upgrade | Mizuho | Neutral → Outperform |
| Mar-09-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-09-26 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-03-26 | Downgrade | Mizuho | Outperform → Neutral |
| Mar-03-26 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-02-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Mar-02-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-24-26 | Initiated | Wolfe Research | Peer Perform |
| Jan-28-26 | Initiated | Barclays | Equal Weight |
| Nov-04-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-14-25 | Upgrade | Mizuho | Neutral → Outperform |
| Apr-01-25 | Resumed | Chardan Capital Markets | Buy |
| Dec-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Feb-29-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-19-23 | Downgrade | Mizuho | Buy → Neutral |
| Mar-17-22 | Upgrade | UBS | Neutral → Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-01-21 | Upgrade | Mizuho | Neutral → Buy |
| Jan-07-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-24-20 | Initiated | H.C. Wainwright | Buy |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Nov-09-20 | Initiated | Jefferies | Buy |
| Nov-04-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-20 | Initiated | Raymond James | Strong Buy |
| Jul-31-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jun-25-20 | Downgrade | Mizuho | Buy → Neutral |
| Jun-25-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-25-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-03-19 | Initiated | Cowen | Outperform |
| Dec-03-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Outperform |
| Oct-11-19 | Initiated | Stifel | Buy |
| Sep-25-19 | Initiated | Bernstein | Outperform |
| Sep-12-19 | Initiated | Mizuho | Buy |
| Jul-30-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-08-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
View All
Uniqure Nv Stock (QURE) Latest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc.CLPT - GlobeNewswire Inc.
uniQure NV (UQ1.SG) Analyst Insights, Price Targets & RecommendationsYahoo Finance - Yahoo! Finance Canada
uniQure N.V. (QURE) interactive stock chart – Yahoo Finance - Yahoo Finance Singapore
Gene Therapy Data Could Be A Big Moment For uniQure Stock (QURE) - Simply Wall Street
UNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 37.3% Share Drop - Business Wire
uniQure N.V. (QURE) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review
UniQure Shares Fall After Barclays Downgrade - marketscreener.com
Barclays Downgrades UniQure to Equal Weight From Overweight - Moomoo
Uniqure N.v Stock Price Forecast. Should You Buy QURE? - StockInvest.us
Why a Huntington’s patient isn’t fazed by the waning effect of UniQure’s gene therapy - STAT
$uniQure NV (QURE.US)$ - Moomoo
UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights - GlobeNewswire
UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights - GlobeNewswire Inc.
uniQure: A Speculative Buy After Huntington's Disease Trial's 4-Year Data Update - Seeking Alpha
uniQure Plunges on Additional Data From Huntington's Disease Study - Zacks Investment Research
uniQure Plunges on Additional Data From Huntington's Disease Study - Yahoo Finance
uniQure Stock Plunges On 4-Year Data, But The Approval Path Is Intact (Rating Upgrade) - Seeking Alpha
EBITDA of uniQure N.V. – HAN:UQ1 - TradingView
Return on invested capital % of uniQure N.V. – HAN:UQ1 - TradingView
uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE) - Morningstar
Four-year data raise durability questions for uniQure’s Huntington gene therapy - biocentury.com
uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE) - PR Newswire
uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE) - The Transylvania Times
uniQure: Another Selloff On 48-Month Huntington Data; I Am (Marginally) Bullish (QURE) - Seeking Alpha
uniQure N.V. (QURE) Discusses Additional Data from Phase I/II AMT-130 Study in Huntington's Disease Highlighting Disease Progression SlowingSlideshow (NASDAQ:QURE) 2026-09-29 - Seeking Alpha
QURE Investor Alert: uniQure Securities InvestigationKehoe Law Firm, P.C. - GlobeNewswire Inc.
Why Is uniQure Stock Sinking on Tuesday? - benzinga.com
Why Is uniQure Stock Sinking on Tuesday? - Yahoo Finance
uniQure Highlights Long-Term AMT-130 Huntington’s Data - TipRanks
uniQure Shares Fall 64% After 48-Month AMT-130 Huntington’s Disease Trial Update - finance.yahoo.com
ClearPoint Neuro Shares Fall 24% Following uniQure AMT-130 Trial Update - finance.yahoo.com
uniQure: 80% Slowing on Huntington's Score at 3 Years - Stock Titan
QURE Stock Is On Track To Shed About Half Its Market Cap Despite Encouraging Huntington’s Disease Data – Here’s What Investors Need To Know - finance.yahoo.com
uniQure plunges 65% as 48-month Huntington’s gene therapy data misses key stat - finance.yahoo.com
uniQure posts new data for Huntington’s disease drug (QURE) - Seeking Alpha
Why is uniQure stock collapsing today? - Investing.com
uniQure Announces Additional Data from Ongoing Phase I/II - globenewswire.com
UniQure’s gene therapy continues to slow Huntington’s progression after four years - STAT
UniQure Sinks After Worse-Than-Expected Huntington’s Results - Bloomberg.com
uniQure (NasdaqGS:QURE) Stock Forecast & Analyst Predictions - Simply Wall Street
uniQure stock falls 10.38 percent as cash reaches USD 810.3 million - AD HOC NEWS
Why is uniQure stock sliding today? - Investing.com
QURE Stock Just Shot Up 8%uniQure’s Much-Talked-About Huntington’s Disease Therapy Gets A UK Boost - Stocktwits
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 - Stocktwits
uniQure N.V. (QURE) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
UniQure N.V. (QURE) Stock Analysis: A Biotech Powerhouse With A 56% Upside Potential - DirectorsTalk Interviews
What to expect from UniQure’s upcoming Huntington’s gene therapy readout - STAT
uniQure (QURE) Submitted AMT-130 for Accelerated Approval in Huntington’s Disease. Can Externally Controlled Data Support the Application? - Yahoo Finance
uniQure Submits BLA for Gene Therapy in HD, AAN, AHS Issue Updated Guideline on Migraine Prevention, CTE Prevalence, Brain Donation Findings in Former NFL Players - NeurologyLive
Liquidity Mapping Around (QURE) Price Events - Stock Traders Daily
Uniqure Nv Stock (QURE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Uniqure Nv Stock (QURE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kapusta Matthew C | Officer |
Jul 02 '26 |
Proposed Sale |
45.15 |
21,082 |
951,932 |
0 |
| Kapusta Matthew C | CEO, Managing Director |
Jul 02 '26 |
Sale |
45.16 |
21,082 |
952,051 |
519,227 |
| Kaye Jack | Director |
Jun 30 '26 |
Option Exercise |
23.44 |
21,167 |
496,230 |
43,056 |
| Kaye Jack | Director |
Jun 30 '26 |
Sale |
46.44 |
21,167 |
983,030 |
25,996 |
| Abi-Saab Walid | Chief Medical Officer |
Jun 30 '26 |
Option Exercise |
5.59 |
10,000 |
55,900 |
178,235 |
| Abi-Saab Walid | Chief Medical Officer |
Jun 30 '26 |
Sale |
46.42 |
30,000 |
1,392,600 |
148,235 |
| Abi-Saab Walid | Chief Medical Officer |
Jun 30 '26 |
Proposed Sale |
46.42 |
30,000 |
1,392,643 |
0 |
| Kaye Jack | Director |
Jun 30 '26 |
Proposed Sale |
46.44 |
21,167 |
983,033 |
0 |
| Abi-Saab Walid | Chief Medical Officer |
Jun 26 '26 |
Sale |
46.86 |
1,434 |
67,197 |
168,235 |
| Abi-Saab Walid | Chief Medical Officer |
Jun 26 '26 |
Proposed Sale |
46.86 |
1,434 |
67,197 |
0 |
1.61%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):